Literature DB >> 17194829

Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.

Regina B Osih1, Jessina C McGregor, Shayna E Rich, Anita C Moore, Jon P Furuno, Eli N Perencevich, Anthony D Harris.   

Abstract

The impact of appropriate empirical antimicrobial therapy for Pseudomonas aeruginosa bacteremia on patient outcomes has not been clearly established. We assessed the effect of appropriate empirical therapy on in-hospital mortality and length of stay (LOS) among patients with P. aeruginosa bacteremia. This was a retrospective cohort study of inpatients with a positive blood culture for P. aeruginosa between January 2001 and June 2005. Empirical therapy was defined as appropriate if the patient received an antibiotic the organism was susceptible to between 8 h before culture collection and the time the susceptibility results were available. The severity of the illness was measured 24 h before culture collection. The data were analyzed using logistic regression (in-hospital mortality) and linear regression (LOS). Overall, there were 167 episodes of P. aeruginosa bacteremia, 123 (86%) of which received appropriate empirical antibiotics. Sixty-one patients died (36.5%). The median time from culture collection to susceptibility results was 3.4 days. After we adjusted for age, severity of illness, and time at risk, we found that the appropriate empirical therapy was not significantly associated with mortality (odds ratio = 0.96; 95% confidence interval = 0.31 to 2.93). There was a 7% reduction in the mean LOS for patients who had received appropriate therapy at the time susceptibility results were available compared to those who did not (P = 0.74). These data suggest that the use of appropriate empirical therapy, i.e., before susceptibility results are known may not be as critical to patient outcomes as other studies have suggested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194829      PMCID: PMC1803143          DOI: 10.1128/AAC.00901-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Excess shock and mortality in Staphylococcus aureus related to methicillin resistance.

Authors:  E N Perencevich
Journal:  Clin Infect Dis       Date:  2000-11       Impact factor: 9.079

2.  A two-year analysis of risk factors and outcome in patients with bloodstream infection.

Authors:  Andrea Endimiani; Antonio Tamborini; Francesco Luzzaro; Gianluigi Lombardi; Antonio Toniolo
Journal:  Jpn J Infect Dis       Date:  2003-02       Impact factor: 1.362

3.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  Causation and causal inference in epidemiology.

Authors:  Kenneth J Rothman; Sander Greenland
Journal:  Am J Public Health       Date:  2005       Impact factor: 9.308

5.  Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections.

Authors:  Ebbing Lautenbach; Neil O Fishman; Warren B Bilker; Analia Castiglioni; Joshua P Metlay; Paul H Edelstein; Brian L Strom
Journal:  Arch Intern Med       Date:  2002-11-25

6.  Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; Eli Perencevich; Mary-Claire Roghmann; Glenn Morris; Keith S Kaye; Judith A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.

Authors:  I Chatzinikolaou; D Abi-Said; G P Bodey; K V Rolston; J J Tarrand; G Samonis
Journal:  Arch Intern Med       Date:  2000-02-28

8.  Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

9.  The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit.

Authors:  R Zaragoza; A Artero; J J Camarena; S Sancho; R González; J M Nogueira
Journal:  Clin Microbiol Infect       Date:  2003-05       Impact factor: 8.067

10.  Preoperative drug dispensing as predictor of surgical site infection.

Authors:  K S Kaye; K Sands; J G Donahue; K A Chan; P Fishman; R Platt
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

View more
  32 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.

Authors:  L A Ruiz; A Gómez; C Jaca; L Martínez; B Gómez; R Zalacain
Journal:  Infection       Date:  2010-09-29       Impact factor: 3.553

3.  Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Authors:  Thomas P Lodise; Nimish Patel; Andrea Kwa; Jeffrey Graves; Jon P Furuno; Eileen Graffunder; Ben Lomaestro; Jessina C McGregor
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Evaluating antibiotic stewardship programs in patients with bacteremia using administrative data: a cohort study.

Authors:  J Boel; M Søgaard; V Andreasen; J O Jarløv; M Arpi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

5.  Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder.

Authors:  Aurélien Dinh; Benjamin Davido; Ruxandra Calin; Julie Paquereau; Clara Duran; Frédérique Bouchand; Véronique Phé; Emmanuel Chartier-Kastler; Martin Rottman; Jérôme Salomon; Patrick Plésiat; Anaïs Potron
Journal:  Spinal Cord Ser Cases       Date:  2017-05-11

6.  Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients.

Authors:  Marin L Schweizer; Jon P Furuno; George Sakoulas; J Kristie Johnson; Anthony D Harris; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

7.  Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Authors:  Kerri A Thom; Michelle D Shardell; Regina B Osih; Marin L Schweizer; Jon P Furuno; Eli N Perencevich; Jessina C McGregor; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

8.  Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; George Sakoulas; Eli N Perencevich
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

9.  Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia.

Authors:  Michael Y Lin; Robert A Weinstein; Bala Hota
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

10.  Morbidity associated with Pseudomonas aeruginosa bloodstream infections.

Authors:  Marc H Scheetz; Michael Hoffman; Maureen K Bolon; Grant Schulert; Wendy Estrellado; Ioannis G Baraboutis; Padman Sriram; Minh Dinh; Linda K Owens; Alan R Hauser
Journal:  Diagn Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.